Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

COI Statement

J. J. K. reports grants and personal fees from AOP Health, and personal fees from Novartis, BMS/Celgene, AbbVie, and PharmaEssentia. J. M. reports grants from AOP Health. R. K. reports personal fees from AOP Health, PharmaEssentia, Qiagen, and Novartis, and stock ownership in MyeloPro Diagnostics and Research. H. H. reports Data Monitoring Board honoraria from AOP Health and grants from Novartis. C. K., K. K., and V. E. report that they are employees of AOP Health. H. G. reports grants and personal fees from AOP Health and Novartis, and personal fees from BMS‐Pharma. The remaining authors have no conflicts of interest to disclose.

References:

• Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141(16):1934‐1942.
• Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood. 2022;139(19):2871‐2881. 10.1182/blood.2022015680
• Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534‐3544.
• Guglielmelli P, Mora B, Gesullo F, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99:1550‐1559.
• Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa‐2b versus standard therapy for polycythaemia vera (PROUD‐PV and CONTINUATION‐PV): a randomised, non‐inferiority, phase 3 trial and its extension study. Lancet Haematol. Mar 2020;7(3):e196‐e208. 10.1016/S2352-3026(19)30236-4